JP2003519181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003519181A5 JP2003519181A5 JP2001549654A JP2001549654A JP2003519181A5 JP 2003519181 A5 JP2003519181 A5 JP 2003519181A5 JP 2001549654 A JP2001549654 A JP 2001549654A JP 2001549654 A JP2001549654 A JP 2001549654A JP 2003519181 A5 JP2003519181 A5 JP 2003519181A5
- Authority
- JP
- Japan
- Prior art keywords
- blood pressure
- melatonin
- pharmaceutical formulation
- antihypertensive
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 8
- 239000002220 antihypertensive agent Substances 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 8
- 229960003987 melatonin Drugs 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- -1 anenolol Chemical compound 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000000422 nocturnal effect Effects 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000031240 Uraemic neuropathy Diseases 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2000/000009 WO2001049286A1 (en) | 2000-01-05 | 2000-01-05 | Method and formulation for treating resistance to antihypertensives and related conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003519181A JP2003519181A (ja) | 2003-06-17 |
| JP2003519181A5 true JP2003519181A5 (https=) | 2011-02-03 |
| JP4996803B2 JP4996803B2 (ja) | 2012-08-08 |
Family
ID=11042938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001549654A Expired - Lifetime JP4996803B2 (ja) | 2000-01-05 | 2000-01-05 | 抗高血圧剤に対する抵抗性及び関連状態を処置する方法及び処方物 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7332177B1 (https=) |
| EP (1) | EP1272177B1 (https=) |
| JP (1) | JP4996803B2 (https=) |
| CN (1) | CN1414851A (https=) |
| AT (1) | ATE359072T1 (https=) |
| AU (1) | AU782266B2 (https=) |
| BG (1) | BG65637B1 (https=) |
| BR (1) | BR0016918A (https=) |
| CA (1) | CA2396129C (https=) |
| CY (2) | CY1108018T1 (https=) |
| CZ (1) | CZ299931B6 (https=) |
| DE (1) | DE60034373T2 (https=) |
| DK (1) | DK1272177T3 (https=) |
| EA (1) | EA004679B1 (https=) |
| EE (1) | EE200200379A (https=) |
| ES (1) | ES2284471T3 (https=) |
| HK (1) | HK1052655A1 (https=) |
| HU (1) | HU227002B1 (https=) |
| IL (1) | IL150190A0 (https=) |
| IS (1) | IS6439A (https=) |
| MX (1) | MXPA02005783A (https=) |
| NO (1) | NO322567B1 (https=) |
| NZ (1) | NZ520078A (https=) |
| PL (1) | PL201219B1 (https=) |
| PT (1) | PT1272177E (https=) |
| SI (1) | SI1272177T1 (https=) |
| SK (1) | SK287508B6 (https=) |
| TR (1) | TR200201724T2 (https=) |
| TW (1) | TWI260983B (https=) |
| UA (1) | UA77394C2 (https=) |
| WO (1) | WO2001049286A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144900A (en) * | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| US20050020666A1 (en) * | 2003-07-25 | 2005-01-27 | Dabur Research Foundation | Cardioprotective agents |
| US20050137247A1 (en) * | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| JP3964417B2 (ja) | 2004-09-27 | 2007-08-22 | 国立大学法人金沢大学 | インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤 |
| KR101053780B1 (ko) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 |
| US20130325151A1 (en) * | 2010-10-25 | 2013-12-05 | Uico, Llc | Control system with solid state touch sensor for complex surface geometry |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
| WO2018033546A1 (en) * | 2016-08-18 | 2018-02-22 | Koninklijke Philips N.V. | Blood-pressure management |
| US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| JP6830156B2 (ja) | 2016-10-31 | 2021-02-17 | ニューリム・ファーマシューティカルズ・リミテッドＮｅｕｒｉｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． | メラトニンミニタブレットおよびその製造方法 |
| WO2019038586A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | PHARMACEUTICAL COMPOSITION OF MELATONIN |
| ES2724933A1 (es) * | 2018-03-13 | 2019-09-17 | Ocupharm Diagnostics Sl | Terapia combinada con melatonina para la reducción de la presión intraocular |
| GB2617102A (en) * | 2022-03-29 | 2023-10-04 | John Hemming Trading Ltd | Sleep therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2134789T3 (es) * | 1991-05-09 | 1999-10-16 | Neurim Pharma 1991 | Composiciones que contienen melatonina. |
| CA2116036A1 (en) * | 1991-10-18 | 1993-04-29 | F. Eugene Yates | Device for the transdermal administration of melatonin |
| US5646049A (en) * | 1992-03-27 | 1997-07-08 | Abbott Laboratories | Scheduling operation of an automated analytical system |
| DE69303919T2 (de) * | 1992-04-07 | 1997-01-30 | Neurim Pharma 1991 | Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie |
| EP0664339A4 (en) * | 1993-07-09 | 1999-04-28 | Wakunaga Seiyaku Kk | METHOD FOR DISCRIMINATION OF NUCLEIC ACIDS AND TEST KIT FOR THIS PURPOSE. |
| MD1716C2 (ro) | 1995-02-01 | 2002-02-28 | Neurim Pharmaceuticals (1991) Ltd. | Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine |
| US5648727A (en) * | 1995-10-24 | 1997-07-15 | Dpc Cirrus Inc. | Capacitive level sensing pipette probe |
| US5700828A (en) | 1995-12-07 | 1997-12-23 | Life Resuscitation Technologies, Inc. | Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions |
| AU2583397A (en) * | 1996-04-10 | 1997-10-29 | Chronorx, Llc | Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions |
| RU2134108C1 (ru) | 1998-10-06 | 1999-08-10 | Заславская Рина Михайловна | Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии |
-
2000
- 2000-01-05 MX MXPA02005783A patent/MXPA02005783A/es active IP Right Grant
- 2000-01-05 JP JP2001549654A patent/JP4996803B2/ja not_active Expired - Lifetime
- 2000-01-05 SI SI200030958T patent/SI1272177T1/sl unknown
- 2000-01-05 AU AU18882/00A patent/AU782266B2/en not_active Expired
- 2000-01-05 CZ CZ20022346A patent/CZ299931B6/cs not_active IP Right Cessation
- 2000-01-05 TR TR2002/01724T patent/TR200201724T2/xx unknown
- 2000-01-05 BR BR0016918-8A patent/BR0016918A/pt not_active IP Right Cessation
- 2000-01-05 EP EP00900110A patent/EP1272177B1/en not_active Expired - Lifetime
- 2000-01-05 IL IL15019000A patent/IL150190A0/xx unknown
- 2000-01-05 SK SK973-2002A patent/SK287508B6/sk not_active IP Right Cessation
- 2000-01-05 HK HK03105037.1A patent/HK1052655A1/zh unknown
- 2000-01-05 PT PT00900110T patent/PT1272177E/pt unknown
- 2000-01-05 NZ NZ520078A patent/NZ520078A/en not_active IP Right Cessation
- 2000-01-05 US US10/169,467 patent/US7332177B1/en not_active Expired - Lifetime
- 2000-01-05 WO PCT/IL2000/000009 patent/WO2001049286A1/en not_active Ceased
- 2000-01-05 DE DE60034373T patent/DE60034373T2/de not_active Expired - Lifetime
- 2000-01-05 HU HU0204089A patent/HU227002B1/hu unknown
- 2000-01-05 EA EA200200738A patent/EA004679B1/ru not_active IP Right Cessation
- 2000-01-05 EE EEP200200379A patent/EE200200379A/xx unknown
- 2000-01-05 AT AT00900110T patent/ATE359072T1/de active
- 2000-01-05 CA CA2396129A patent/CA2396129C/en not_active Expired - Lifetime
- 2000-01-05 DK DK00900110T patent/DK1272177T3/da active
- 2000-01-05 CN CN00818153A patent/CN1414851A/zh active Pending
- 2000-01-05 ES ES00900110T patent/ES2284471T3/es not_active Expired - Lifetime
- 2000-01-05 PL PL356325A patent/PL201219B1/pl unknown
- 2000-05-01 UA UA2002076326A patent/UA77394C2/uk unknown
-
2001
- 2001-07-10 TW TW090116904A patent/TWI260983B/zh not_active IP Right Cessation
-
2002
- 2002-06-24 IS IS6439A patent/IS6439A/is unknown
- 2002-06-27 NO NO20023102A patent/NO322567B1/no not_active IP Right Cessation
- 2002-08-05 BG BG106978A patent/BG65637B1/bg unknown
-
2007
- 2007-07-10 CY CY20071100916T patent/CY1108018T1/el unknown
- 2007-12-04 US US11/950,039 patent/US8075914B2/en not_active Expired - Fee Related
- 2007-12-18 CY CY200700033C patent/CY2007033I1/el unknown
-
2011
- 2011-10-25 US US13/281,212 patent/US8728511B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003519181A5 (https=) | ||
| JP2022009125A5 (https=) | ||
| WO2007098387A3 (en) | Antihypertensive therapy | |
| JP2007514750A5 (https=) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2006518731A5 (https=) | ||
| JP4896334B2 (ja) | 睡眠時呼吸障害を治療及び診断する方法並びにその方法を実施する手段 | |
| WO2022271611A1 (en) | Methods for treating obstructive sleep apnea | |
| JP4996803B2 (ja) | 抗高血圧剤に対する抵抗性及び関連状態を処置する方法及び処方物 | |
| AU2005212149B2 (en) | Method of treating and diagnosing sleep disordered breathing using zonisamide and means for carrying out the method | |
| JP2002544227A5 (https=) | ||
| Temel Koksal et al. | Alternative restorative approach for treatment of patient with extremely worn dentition | |
| MXPA06014885A (es) | Nueva asociacion de un ihnibidor de la corriente sinusal if y de un inhibidor de la enzima de conversion y las composiciones farmaceuticas que la contienen. | |
| RU2004137109A (ru) | Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда | |
| WO2017121432A1 (en) | Tesofensine and metoprolol for treatment of hypertension | |
| Calvo et al. | P-123: Administration time-dependent effects of torasemide on ambulatory blood pressure in patients with essential hypertension | |
| Calvo et al. | P-122: Chronotherapy improves blood pressure control and reverts the non-dipper pattern in patients with resistant hypertension | |
| Lacourciere | Extended therapeutic control in essential hypertension: comparison of the impact of missed doses of tasosartan and losartan | |
| JPS60155115A (ja) | 血圧上昇剤 | |
| Wright et al. | P-256: β-Blockers in combination with renin antiotensin system blockade facilitate attaining blood pressure goals with differences in metabolic consequences | |
| Stokes | P-256 A: Adjuvant isosorbide mononitrate lowers systolic blood pressure long-term in elderly patients with ISH refractory to combination therapy | |
| Downes et al. | Diltiazem induced vasoplegic shock managed with high dose pressors and methylene blue | |
| Calvo et al. | P-208: Effects of morning versus evening administration of valsartan on ambulatory blood pressure in elderly hypertensive patients | |
| Hermida et al. | P-205: Administration time-dependent effects on ambulatory blood pressure of doxazosin gits as added therapy in uncontrolled hypertensive patients | |
| Sirenko et al. | P-253: Antihypertensive effectiveness of the valsartan and its influence on morning surge in patients with mild to moderate arterial hypertension |